Multiple registrational trials are planned to start in 2024 and 2025, evaluating BNT327/PM8002 plus chemotherapy in various solid tumour ... is a global next generation immunotherapy company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback